Logo Freelancer.com
Zaloguj się Zarejestruj się
Opublikuj Projekt
ODKRYWAJ
Article Writing
Business Plans
Data Entry
Finance
Research Writing
Zdjęcie profilowe
Zacząłeś obserwować
Błąd związany z obserwowaniem użytkownika.
Ten użytkownik nie pozwala użytkownikom na obserwowanie go.
Już obserwujesz tego użytkownika.
Twój abonament pozwala na obserwowanie 0 projektów. Zmień poziom abonamentu na wyższy tutaj.
Udało się przestać obserwować
Błąd w zakończeniu obserwowania użytkownika.
Udało Ci się polecić
Błąd podczas polecania użytkownika
Coś poszło nie tak. Proszę odświeżyć stronę i spróbować ponownie.
Udało się zweryfikować adres e-mail.
Awatar Użytkownika

Corey D.

@coreyd5

0,0
0
0,0
0,0
0%

Helping build tech-enabled healthcare companies

$50 USD / godz.
・
Flaga
United States (8:08 PM)
・
Dołączył/a listopada 30, 2024
$50 USD / godz.
・
Innovative and results-driven executive with extensive experience in healthcare-focused leadership, corporate development, mergers and acquisitions (M&A), and strategic consulting. Proven track record of driving growth for companies ranging from startups to publicly traded organizations. Adept at identifying undervalued opportunities, building partnerships, and managing complex transactions. Expertise in business development, DTC marketing, operations and market research.
Weryfikacje
Freelancer Data Entry Clerks United States
Wyświetl Wszystkie Data Entry Clerks w United States

Portfolio

Portfolio

12386338
Since founding Medically Modern Inc. in June 2023, I have built a company that provides diabetic supplies to patients nationwide. As the active CEO and sole founder, I have overseen all aspects of the business, which has scaled to a subscription revenue model, currently reaching an annual recurring revenue (ARR) of $2M. We have successfully credentialed and contracted with all major payors, submitting claims directly to them for payment. Additionally, we employ an omnichannel marketing strategy to acquire patients, integrating various platforms and touchpoints to engage with our target audience effectively. With a patient-first approach, we continue to expand and grow, focused on delivering essential diabetic supplies to those in need and enhancing the healthcare experience for our users.
Founded Diabetes Technology Company
12386321
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
12386307
The acquisition of Elusys Therapeutics by Heat Biologics (now NightHawk Biosciences) was a pivotal step in expanding its presence in the biodefense sector. As the lead M&A consultant and advisor, I was responsible for identifying Elusys as a high-value target, conducting financial due diligence, and managing the orchestration of third-party stakeholders. This included analyzing Elusys' revenue streams from $350M+ in U.S. government contracts, mitigating risks tied to these agreements, and ensuring regulatory compliance. I facilitated deal negotiations between Heat Biologics’ board, Elusys’ advisors, and legal counsel, ensuring favorable terms with no stock or warrants issued. Post-acquisition, I oversaw integration planning, including migrating manufacturing of ANTHIM®—a critical anthrax treatment—to NightHawk’s new Kansas facility. The transaction bolstered NightHawk’s capabilities, enhanced operating synergies, and strengthened its RapidVax® platform for addressing emerging biolo
Led Acquistion Biodefense Biologic
12386294
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
12386244
Anchored a $15M equity followed by leading the uplisting efforts to get a DTC telehealth company onto the NASDAQ. Individually raised $3.5M of the $15M through a Special Purpose Vehicle (SPV) via the Healthcare-focused Hedge Fund I founded called Paradigm Opportunities. Efforts included developing the investment thesis, raising capital from 20 LPs, forming the SPV, working alongside management to ensure NASDAQ compliance and monitoring the investment.
Lead Investor In $15M Equity Raise
12386338
Since founding Medically Modern Inc. in June 2023, I have built a company that provides diabetic supplies to patients nationwide. As the active CEO and sole founder, I have overseen all aspects of the business, which has scaled to a subscription revenue model, currently reaching an annual recurring revenue (ARR) of $2M. We have successfully credentialed and contracted with all major payors, submitting claims directly to them for payment. Additionally, we employ an omnichannel marketing strategy to acquire patients, integrating various platforms and touchpoints to engage with our target audience effectively. With a patient-first approach, we continue to expand and grow, focused on delivering essential diabetic supplies to those in need and enhancing the healthcare experience for our users.
Founded Diabetes Technology Company
12386321
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
The business development work I conducted across these companies reflects a consistent focus on driving strategic growth, executing high-impact transactions, and building value through partnerships, joint ventures, and M&A. Below is an overview of my contributions: Semler Scientific: 1) Led all initiatives to identify acquisition targets, partnerships, and joint ventures. 2) Conducted extensive market research and valuation analysis, uncovering high-impact growth opportunities. NightHawk Biosciences, Inc: Directed strategic contracting for financing commercial biodefense assets and securing government contracts. Scorpius BioManufacturing: Oversaw business development for a large-molecule CDMO, forging strategic relationships with pharmaceutical companies to expand market reach and revenue. iSpecimen: 1) Led M&A initiatives, joint ventures, and partnerships to foster inorganic growth. 2) Identified and implemented cost-saving measures and operational strategies for profitabi
Led BD For 6 Healthcare Companies
12386307
The acquisition of Elusys Therapeutics by Heat Biologics (now NightHawk Biosciences) was a pivotal step in expanding its presence in the biodefense sector. As the lead M&A consultant and advisor, I was responsible for identifying Elusys as a high-value target, conducting financial due diligence, and managing the orchestration of third-party stakeholders. This included analyzing Elusys' revenue streams from $350M+ in U.S. government contracts, mitigating risks tied to these agreements, and ensuring regulatory compliance. I facilitated deal negotiations between Heat Biologics’ board, Elusys’ advisors, and legal counsel, ensuring favorable terms with no stock or warrants issued. Post-acquisition, I oversaw integration planning, including migrating manufacturing of ANTHIM®—a critical anthrax treatment—to NightHawk’s new Kansas facility. The transaction bolstered NightHawk’s capabilities, enhanced operating synergies, and strengthened its RapidVax® platform for addressing emerging biolo
Led Acquistion Biodefense Biologic
12386294
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
As the Chief Business Officer of LifeMD (NASDAQ: LFMD) I led the launch of LifeMD’s virtual care division, overseeing its development from inception to launch. My role included orchestrating the efforts of multiple teams, such as marketing, finance, development, and operations, ensuring that every aspect of the project was seamlessly integrated. From conceptualizing the platform to coordinating a phased rollout, I ensured that every piece was tied together into a cohesive and fluid operation, enabling the division to launch on time and succesfully. At launch, LifeMD’s virtual care platform delivers 24/7 access to affordable, patient-centric care nationwide. Patients were paired with primary care physicians and medical teams, gaining unlimited messaging, on-demand consultations, and discounted prescription medications. By streamlining the onboarding process and utilizing telehealth technology, the platform provided patients with quick, convenient access to their personalized care team.
Telehealth Business Division Launch
12386244
Anchored a $15M equity followed by leading the uplisting efforts to get a DTC telehealth company onto the NASDAQ. Individually raised $3.5M of the $15M through a Special Purpose Vehicle (SPV) via the Healthcare-focused Hedge Fund I founded called Paradigm Opportunities. Efforts included developing the investment thesis, raising capital from 20 LPs, forming the SPV, working alongside management to ensure NASDAQ compliance and monitoring the investment.
Lead Investor In $15M Equity Raise
Zmiany zapisane
0.0 · 0 Reviews
Oceny
Brak ocen do zobaczenia!
Zaproszenie wysłane pomyślnie!
Dziękujemy! Przesłaliśmy Ci e-mailem link do odebrania darmowego bonusu.
Coś poszło nie tak podczas wysyłania wiadomości e-mail. Proszę spróbować ponownie.
Logo Freelancer.com Poland / Polski
Pomoc i Wsparcie
 Freelancer
Kategorie Projekty Konkursy Freelancerzy Enterprise Rozwój Sztucznej Inteligencji Abonament Program Ulubionych Freelancerów Zarządzanie projektami Projekty lokalnePhoto Anywhere Prezentacja Interfejs API dla deweloperów Przejdź proces weryfikacji Aplikacja komputerowa
 Na temat
Informacje o nas Jak to działa Ochrona Inwestor Mapa strony internetowej Historie Wiadomości Zespół Nagrody Materiały prasowe Kariera
 Warunki
Polityka Prywatności Warunki świadczeń usług Polityka dotycząca praw autorskich Zasady postępowania Opłaty i prowizje
 Partnerzy
Escrow.com Loadshift Warrior Forum
Aplikacje
Logo Apple App StoreLogo Google Play
Nie udało się skopiować do schowka. Proszę, spróbować ponownie po dostosowaniu uprawnień.
Skopiowane do schowka.
Zarejestrowani Użytkownicy Całkowita Liczba Opublikowanych Projektów
Freelancer ® is a registered Trademark of Freelancer Technology Pty Limited (ACN 142 189 759)
Copyright © 2025 Freelancer Technology Pty Limited (ACN 142 189 759)
Wczytywanie podglądu
Udzielono pozwolenia na Geolokalizację.
Twoja sesja logowania wygasła i zostałeś wylogowany. Proszę, zalogować się ponownie.